Bacterial Pneumonia Clinical Trial
Official title:
Use of a Novel Protein (sTREM-1) to Differentiate Pure Viral Lung Infection From Viral With Co-existing Bacterial Lung Infection
The purpose of this study is to determine whether a protein called TREM-1 can be used to differentiate viral and bacterial pneumonias in children who are on ventilator support. We propose that the level of TREM-1 will be significantly elevated in the lung fluid of children with bacterial pneumonia and viral with co-existing bacterial pneumonia than in children with pure viral pneumonia.
Most often, viruses are the cause of pneumonia in children. However, viral pneumonias are
frequently associated with secondary bacterial pneumonia. It is important, though difficult,
to differentiate patients who only have viral pneumonia from those who have viral pneumonia
with secondary bacterial pneumonia. This will help physicians to prescribe antibiotics to
only those with bacterial pneumonia and avoid antibiotic use in those with pure viral
pneumonia, thus help to limit health-care cost and to decrease emergence of antibiotic
resistance. In adult studies, TREM-1 has been shown to be specifically expressed in bacterial
infections.
We propose that measuring TREM-1 in the bronchoalveolar lavage (BAL) fluid will help to
differentiate these groups. Our hypothesis is that concentration of TREM-1 will be
significantly elevated in the BAL fluid of children with bacterial pneumonia and viral with
co-existing bacterial pneumonia than in children with pure viral pneumonia.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01570192 -
Clinical Trials to Reduce the Risk of Antimicrobial Resistance
|
Phase 2 | |
Recruiting |
NCT04952337 -
Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)
|
||
Completed |
NCT02493764 -
Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
|
Phase 3 | |
Completed |
NCT02531438 -
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
|
Phase 3 | |
Completed |
NCT00079885 -
Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia
|
Phase 3 | |
Recruiting |
NCT05629741 -
A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101
|
Phase 1 | |
Completed |
NCT05417997 -
Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients
|
Phase 3 | |
Completed |
NCT00509106 -
Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia
|
Phase 3 | |
Completed |
NCT00080496 -
Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia
|
Phase 3 | |
Completed |
NCT03158727 -
Cx611-0204 SEPCELL Study
|
Phase 1/Phase 2 | |
Completed |
NCT00621504 -
Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia
|
Phase 3 | |
Completed |
NCT00124020 -
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
|
Phase 3 | |
Completed |
NCT00081575 -
Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia
|
Phase 3 | |
Completed |
NCT00451386 -
Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)
|
Phase 2 | |
Recruiting |
NCT03752320 -
Multiplex Polymerase Chain Reaction in Postoperative Pneumonia After Thoracic Surgery
|
||
Active, not recruiting |
NCT04779242 -
Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
|
Phase 3 | |
Completed |
NCT00763620 -
Assessment of the Diagnostic Capacity of the Mini-broncho Alveolar Lavage Performed Through a Suction Catheter
|
N/A | |
Completed |
NCT00107952 -
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
|
Phase 3 | |
Terminated |
NCT03862040 -
Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia
|
Phase 1 | |
Recruiting |
NCT05531149 -
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
|
Phase 3 |